Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomaglumetad methionil

Drug Profile

Pomaglumetad methionil

Alternative Names: DB103; LY 2140023; LY 2812223; LY 404039 prodrug; LY2140023 monohydrate; mGlu 2/3; mGlu2/3 pro II

Latest Information Update: 29 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Denovo Biopharma; Eli Lilly; National Institute on Drug Abuse; New York University School of Medicine; University of California at Los Angeles
  • Class Amides; Antipsychotics; Carboxylic acids; Drug withdrawal therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse; Schizophrenia
  • Discontinued Post-traumatic stress disorders

Most Recent Events

  • 29 Nov 2018 Denovo Biopharma plans a phase II trial in 2019 (Denovo Biopharma Pipeline, November 2018)
  • 29 Nov 2018 Phase I development is ongoing for Schizophrenia USA
  • 02 Nov 2018 Discontinued - Phase-I for Post-traumatic stress disorders in USA (PO) (NCT02234687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top